BiomX Inc.

Chardan Healthcare Acquisitions Corp, the blank-check company that would later become BiomX Inc. (NYSE American: PHGE), priced its initial public offering in December 2018, with the 424B4 final prospectus filed on December 14, 2018. The SPAC was sponsored by Chardan Healthcare Acquisitions LLC, an affiliate of Chardan Capital Markets, and targeted the healthcare and biotechnology sector. The vehicle subsequently announced a business combination with Israeli phage-therapy developer BiomX Ltd. in May 2019 and closed the transaction in October 2019, at which point the combined company began trading under the PHGE ticker as a clinical-stage biopharmaceutical company. Sign up for SpacDesk to access full deal timelines, sponsor history, and filing analytics for PHGE and thousands of other SPAC transactions.